HLS Therapeutics Inc
HLS
Company Profile
Business description
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, and the United States, and the Rest of the world.
Contact
10 Carlson Court
Suite 701
EtobicokeONM9W 6L2
CANT: +1 647 495-9000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
92
Stocks News & Analysis
stocks
A collection of our best stock opportunities
Our latest articles about where we see opportunities in the market.
stocks
Morningstar analyst reacts to Macquarie Group’s earnings
Banking Analyst Nathan Zaia’s analysis of MQG’s results.
stocks
Undervalued ASX share showing progress in global efforts
More clarity on the path forward in the UK.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,931.70 | 31.80 | -0.35% |
| CAC 40 | 7,800.88 | 33.70 | -0.43% |
| DAX 40 | 23,970.36 | 247.14 | -1.02% |
| Dow JONES (US) | 44,837.56 | 64.36 | -0.14% |
| FTSE 100 | 9,081.44 | 38.87 | -0.43% |
| HKSE | 25,313.22 | 248.91 | -0.97% |
| NASDAQ | 21,178.58 | 70.27 | 0.33% |
| Nikkei 225 | 40,655.54 | 342.73 | -0.84% |
| NZX 50 Index | 12,893.53 | 17.21 | -0.13% |
| S&P 500 | 6,389.77 | 1.13 | 0.02% |
| S&P/ASX 200 | 8,670.40 | 27.30 | -0.31% |
| SSE Composite Index | 3,598.40 | 0.46 | 0.01% |